Fabry disease (FD) is an X-linked lysosomal storage disorder that results from a deficiency of α-galactosidase A activity. This enzymatic defect leads to the progressive accumulation of glycosphingolipids throughout the body and causes multisystemic problems including neurological, ocular, skin, renal, and cardiac manifestations in classical type of FD. The majority of patients with this disease have cardiac involvement that is mainly manifested as left ventricular hypertrophy (LVH). A cardiac variant of FD with late-onset isolated cardiac manifestation has also been recognized. Recent studies have revealed that the prevalence of FD in patients with unexplained LVH is about 1%. Cardiac involvement of FD is associated with significant morbidity and early death due to heart failure or ventricular arrhythmias. As disease-specific enzyme replacement therapy is now available for FD, correct diagnosis is important.
| INTRODUCTION
Fabry disease (FD), also called Anderson-Fabry disease, is an X-linked lysosomal storage disease caused by mutations in the gene encoding the lysosomal enzyme α-galactosidase A (α-Gal A).
1,2 The disease was first described as angiokeratoma corporis diffusum by dermatologist Johannes
Fabry in Germany and by dermatologist William Anderson in England in
1898. Glycolipid accumulation due to deficient activity of α-Gal A occurs in several organs. Although the prevalence of FD in Japan remains unknown, the prevalence of Fabry disease in Western countries is estimated to range from 1:40 000 to 1:117 000 persons. 2, 3 Involvement of the heart, kidney, and brain is particularly important for the prognosis of FD.
Enzyme replacement therapy (ERT) is now available for FD, and outcomes of ERT have been shown in clinical trials and observational studies. 4 ,5
| PATHOPHYSIOLOGY
FD is an X-linked lysosomal storage disorder that results from a deficiency of α-Gal A activity. 1, 2 The disease is caused by mutations in the GLA gene that codes for α-Gal A enzyme, and more than 300 mutations are associated with the disease. This enzymatic defect leads to progressive accumulation of glycosphingolipids, predominantly globotriaosylceramide and globotriaosylsphingosine, in lysosomes in multiple cell types throughout the body and causes multisystemic problems including neurological, ocular, skin, brain, renal, and cardiac manifestations. Although FD is an X-linked disorder, most heterozygous females are now recognized to be affected. 6, 7 This onset of clinical manifestations in females can be explained by a process of X chromosome inactivation, so-called lyonization. X and Y chromosomes are the sex chromosomes of mammals: Female cells contain two X chromosomes, while male cells contain one X chromosome and one Y chromosome. In females, one of the two parental X chromosomes is randomly inactivated in each cell at an early stage of development.
This means that female mammals are mosaics, comprising mixtures of cell lines in which the maternal X is inactivated and cell lines where the paternally inherited X is inactivated. For example, the fur coloration of the tortoiseshell cat can be explained by this phenomenon.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. In both types of FD, LVH is an early cardiac abnormality shown by echocardiography. It has also been reported that a decrease in mitral annulus velocity determined by tissue Doppler imaging occurs before cardiac hypertrophy and that this index is useful for early detection of cardiac abnormality. 9 The LVH pattern is diffuse concentric in most cases, although cases with asymmetric septal hypertrophy have also been reported. 10 Echocardiographic findings in our male patients are shown in Figure 1 . A pressure gradient sometimes arises in the LV mid-ventricle depending on the degree of hypertrophy. In early manifestations of the heart, hypertrophy resembling hypertrophic cardiomyopathy (HCM) occurs, but progression of the hypertrophy causes a decrease in ventricular wall motion, particularly at the base of the posterior wall of the left ventricle, leading to intractable heart failure. Cardiac dysfunctions generally occur about 10 years later in women than in men. As for the relationship between female carriers and cardiomyopathy, it was reported that all of the 25 patients over 45 years of age among 55 female patients diagnosed with FD had LVH. father does not have FD, the mother is likely to be a heterozygote, although not all mothers will be heterozygotes because there are some de novo mutations. 16, 17 Regarding the incidence of FD in cases of LVH of unknown etiology, Nakao et al. 8 measured plasma α-Gal activity in 230 male patients in whom echocardiography showed LVH (wall thickness ≥13 mm) and found reduced enzyme activity in 7 (3%) of the male patients, for whom a diagnosis of FD with late-onset isolated cardiac manifestation was made. A study conducted in the UK also showed reduced enzyme activity in 4% of male patients who were diagnosed with HCM (in 6% of the patients when the cases were limited to late-onset cases with age at the time of diagnosis of HCM being over 40 years). 18 In our hospital, we performed clinical evaluation including measurements of plasma α-Gal A activity in 177 consecutive unrelated male patients with a clinical diagnosis of HCM (maximum LV wall thickness ≥15 mm) and found that the prevalence of FD in our Japanese cohort was 1.1%. 19 Our data are consistent with results of recent studies with larger numbers of patients by means of screening based on low plasma enzymatic activity. 20, 21 Monserrat et al. 20 reported that they screened plasma α-Gal A activity in 328 unrelated male patients with HCM and found a prevalence of FD of 0.9%. Hagege et al. 21 performed systematic screening for FD in patients with a diagnosis of HCM by an α-Gal A assay on dried blood spots using a filter paper test and they identified four FD patients of 278 men (1.4%). Based on the results of studies conducted so far, it can be concluded that FD does exist in patients with cardiac hypertrophy.
| CLINICAL PRESENTATION

| Clinical types
| TREATMENT
Before the establishment of enzyme replacement therapy, only symp- Enzyme replacement therapy has recently been developed as a therapy to improve the deficiency or reduced level of α-Gal activity in patients with FD, and the therapy has been covered by insurance in Japan since 2004. Enzyme replacement therapy has been shown to be effective for eliminating globotriaosylceramide that has accumulated in plasma or tissues. 4, 5 It has been reported that initiation of this therapy before irreversible changes occur in organs can improve organ dysfunction and symptoms. As for its effects on the heart, it has been reported that in patients without myocardial fibrosis assessed by the magnetic resonance imaging late-enhancement technique, enzyme replacement therapy resulted in a significant reduction in left ventricular mass, an improvement in myocardial function as shown by systolic radial strain rate, and a higher exercise capacity obtained by bicycle stress exercise. 22 In contrast, patients with myocardial fibrosis showed a minor reduction in LVH and no improvement in myocardial function or exercise capacity.
Despite drawbacks of the therapy including the need for intravenous administration every 2 weeks, the possibility of hypersensitivity reaction, and high cost of the drug (although the cost burden for the patient is greatly reduced using a system of subsidies for specified patients), enzyme replacement therapy is at present the only effective therapy for FD. However, the effectiveness of the therapy for patients with advanced cardiomyopathy has not been confirmed, and further investigation is needed to determine the effectiveness of enzyme replacement therapy for suppressing disease progression. Studies on chaperone therapy and gene therapy for FD are also currently being conducted.
| SUMMARY
It is thought that many cases of FD have been left undiagnosed. As effective therapy has now been established for this progressive disease that has a poor prognosis, attention must be given to the possibility of FD in patients who have symptoms of FD in childhood such as pain in the extremities and patients who have LVH of unknown etiology.
Early diagnosis and treatment are important for patients with FD.
